drugset / Trial / NCT06499688
A Phase III Study to Evaluate the Efficacy and Safety of Recombinant Botulinum Toxin Type A for Injection in the Treatment of Moderate to Severe Glabellar Lines
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a randomized, double-blind, placebo- and active-controlled parallel-group multi-center phase III study to evaluate the efficacy and safety of Rcombinant botulinum neurotoxin type A for injection (YY001)) in the treatment of moderate to severe glabellar lines.
Timeline
- Start
- 2023-12-28
- Primary completion
- 2024-03-29
- Completion
- 2024-05-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Botulinum toxin type A | Protein / enzyme biologic | 0.25 ml | Intramuscular |
| Subject | YY001 | Protein / enzyme biologic | 0.25 ml | Intramuscular |
Indications
No indication recorded.